Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a specific Traditional Chinese Medicine (TCM) herbal formulation developed at Wangjing Hospital, China Academy of Chinese Medical Sciences, for the treatment of chronic atrophic gastritis (CAG). The prescription is a complex mixture of 18 herbs, including *Pinellia ternata*, *Scutellaria baicalensis*, *Coptis chinensis*, and *Astragalus membranaceus*. It is designed to address the histological changes associated with CAG, such as glandular atrophy and intestinal metaplasia. The formulation likely works through multi-target mechanisms, including anti-inflammatory, antioxidant, and mucosal protective effects, as well as potentially modulating the gastric microbiota. It was evaluated in a Phase 2 clinical trial (NCT02955134) comparing its efficacy against placebo and standard care (hydrotalcite) in patients aged 40-65 years with pathologically confirmed CAG.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chinese medicine prescription (Wangjing Hospital).